Rova-T Enhances the Anti-Tumor Activity of Anti-PD1 in a Murine Model of Small Cell Lung Cancer with Endogenous Dll3 Expression
Vitorino, P., Chuang, C. H., Iannello, A., Zhao, X., Anderson, W., Ferrando, R., ... & Saunders, L. R. (2021). Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression. Translational oncology, 14(1), 100883.
Authors: Philip Vitorino 1, Chen-Hua Chuang 2, Alexandre Iannello 3, Xi Zhao 4, Wade Anderson 5, Ronald Ferrando 4, Zhaomei Zhang 4, Shravanthi Madhavan 6, Holger Karsunky 7, Laura R Saunders 8
Online: https://www.sciencedirect.com/science/article/pii/S1936523320303752
Issue: Transl Oncol. 2021 Jan;14(1):100883.
Abstract
Rovalpituzumab tesirine (Rova-T) offers a targeted therapy for ~85% of SCLC patients whose tumors express DLL3, but clinical dosing is limited due to off-target toxicities. We hypothesized that a sub-efficacious dose of Rova-T combined with anti-PD1, which alone shows a clinical benefit to ~15% of SCLC patients, might elicit a novel mechanism of action and extend clinical utility. Using a pre-clinical murine SCLC tumor model that expresses Dll3 and has an intact murine immune system, we found that sub-efficacious doses of Rova-T with anti-PD1 resulted in enhanced anti-tumor activity, compared to either monotherapy. Multiplex immunohistochemistry (IHC) showed CD4 and CD8 T-cells primarily in normal tissue immediately adjacent to the tumor. Combination treatment, but not anti-PD1 alone, increased Ki67+/CD8 T-cells and Granzyme B+/CD8 in tumors by flow cytometry and IHC. Antibody depletion of T-cell populations showed CD8+ T-cells are required for in vivo anti-tumor efficacy. Whole transcriptome analysis as well as flow cytometry and IHC showed that Rova-T activates dendritic cells and increases Ccl5, Il-12, and Icam more than anti-PD1 alone. Increased tumor expression of PDL1 and MHC1 following Rova-T treatment also supports combination with anti-PD1. Mice previously treated with Rova-T + anti-PD1 withstood tumor re-challenge, demonstrating sustained anti-tumor immunity. Collectively our pre-clinical data support clinical combination of sub-efficacious Rova-T with anti-PD1 to extend the benefit of immune checkpoint inhibitors to more SCLC patients.